Gulf International Bank UK Ltd Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Gulf International Bank UK Ltd trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,095 shares of the biopharmaceutical company’s stock after selling 49 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Regeneron Pharmaceuticals were worth $11,223,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in REGN. ARK Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 169.8% during the first quarter. ARK Investment Management LLC now owns 1,218,970 shares of the biopharmaceutical company’s stock valued at $576,743,000 after buying an additional 767,152 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Regeneron Pharmaceuticals by 31.6% during the first quarter. JPMorgan Chase & Co. now owns 3,035,655 shares of the biopharmaceutical company’s stock valued at $1,436,290,000 after acquiring an additional 728,261 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Regeneron Pharmaceuticals by 351.5% in the 1st quarter. Acadian Asset Management LLC now owns 425,374 shares of the biopharmaceutical company’s stock worth $201,262,000 after buying an additional 331,154 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Regeneron Pharmaceuticals by 17.8% during the 1st quarter. Alliancebernstein L.P. now owns 2,077,251 shares of the biopharmaceutical company’s stock valued at $982,831,000 after purchasing an additional 313,907 shares in the last quarter. Finally, Putnam Investments LLC raised its holdings in Regeneron Pharmaceuticals by 54.6% in the 1st quarter. Putnam Investments LLC now owns 655,652 shares of the biopharmaceutical company’s stock worth $310,215,000 after purchasing an additional 231,463 shares during the period. 82.31% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $787.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 20th. Benchmark boosted their target price on Regeneron Pharmaceuticals from $636.00 to $727.00 and gave the stock a “buy” rating in a research report on Monday, August 23rd. SVB Leerink increased their price target on Regeneron Pharmaceuticals from $641.00 to $725.00 and gave the stock an “outperform” rating in a research note on Friday, August 6th. Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $576.00 to $606.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 7th. Finally, BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $625.00 to $669.00 and gave the company an “outperform” rating in a research note on Friday, August 6th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Buy” and an average target price of $685.59.

REGN opened at $639.52 on Tuesday. The company has a fifty day moving average price of $619.90 and a two-hundred day moving average price of $541.48. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.04 and a current ratio of 3.57. The firm has a market capitalization of $68.40 billion, a PE ratio of 11.48, a P/E/G ratio of 0.77 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $441.00 and a 52 week high of $686.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported $25.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $8.81 by $16.99. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $3.90 billion. Regeneron Pharmaceuticals had a return on equity of 50.43% and a net margin of 50.11%. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 51.91 EPS for the current year.

In related news, CEO Leonard S. Schleifer sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 18th. The stock was sold at an average price of $650.03, for a total transaction of $130,006,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Joseph L. Goldstein sold 2,479 shares of the stock in a transaction on Friday, September 10th. The stock was sold at an average price of $650.00, for a total transaction of $1,611,350.00. Following the transaction, the director now owns 8,370 shares of the company’s stock, valued at approximately $5,440,500. The disclosure for this sale can be found here. In the last three months, insiders sold 367,388 shares of company stock worth $226,431,216. 11.84% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Article: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.